N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial

Dataset derived from a 24-week, multi-centre, randomized, double-blind, placebo-controlled trial evaluating the efficacy of N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder (OCD). The dataset involves adult participants (18-75 years) with OCD, who are on stable medication dosages for at least 8 weeks prior to the trial. Participants are randomized to receive either NAC (2,000-4,000mg per day) or placebo, with dosages titrated based on response every 4 weeks. The primary outcome measure is the reduction in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores from baseline. Secondary outcomes include improvements in anxiety, mood, functioning, and overall quality of life.